Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mertiatide→

Mertiatide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
66516-09-4
Molecular formula
C8H13N3O5S
Molecular weight
263.27 g/mol
Drug class
Technetium-99m renal radiopharmaceuticaltubular secretion imaging agent
Mechanism of action
Technetium-99m mertiatide (MAG3) is highly protein-bound but reversibly so, and is rapidly cleared from blood by renal tubular secretion and glomerular filtration. Dynamic renal uptake and excretion are measured by scintigraphy to assess perfusion, function and urinary drainage.
Indications / reported uses
  • Renal scintigraphy to evaluate congenital or acquired renal abnormalities, renal failure, urinary tract obstruction and renal calculi in adults and children.
  • Provides information on overall and split renal function, renal angiograms and renogram curves for whole kidney and renal cortex.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0571c18b-1d5e-47bd-bddf-54d74ce1b442 · https://www.ndf.gov.sg/about-drugs/product-information/sin06741p/ · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D017263 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mertiatide Environmental Risk Assessment (ERA) (the Mertiatide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.